about
Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPDMucosa-dependent muscarinic liberation of prostaglandins from rat isolated tracheaNovel therapy for COPD.Tiotropium bromide.The use of ipratropium bromide for the management of acute asthma exacerbation in adults and children: a systematic review.Pharmacogenetics of asthma.Muscarinic blockade of methacholine induced airway and parenchymal lung responses in anaesthetised rats.A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study GroupParadoxical facilitation of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by isoprenalineTiotropium: a bronchodilator for chronic obstructive pulmonary disease.The activation of M3 mAChR in airway epithelial cells promotes IL-8 and TGF-β1 secretion and airway smooth muscle cell migration.Impairment of small airways in COPD patients with frequent exacerbations and effects of treatment with tiotropium.The development of anticholinergics in the management of COPD.Optimizing bronchodilator therapy in emphysema.Tiotropium for adults with inadequately controlled persistent asthma.Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile.Anticholinergics/antimuscarinic drugs in asthma.The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease.Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.Beta-Adrenergic AgonistsThe nervous system of airways and its remodeling in inflammatory lung diseases.Inhaled Long-acting Anticholinergics and Urinary Tract Infection in Individuals with COPD.Optimizing bronchodilation in the prevention of COPD exacerbationsWhat is the role of nerves in chronic asthma and symptoms?Tiotropium bromide as add-on therapy to inhaled corticosteroids for treating asthma.Tiotropium bromide: an update.Methacholine-induced airway hyperresponsiveness is dependent on Galphaq signaling.Modulation of cholinergic responsiveness through the [beta]-adrenoceptor signal transmission pathway in bovine trachealis.Retinoic acid reverses the airway hyperresponsiveness but not the parenchymal defect that is associated with vitamin A deficiency.The efficacy of nebulized albuterol/ipratropium bromide versus albuterol alone in the prehospital treatment of suspected reactive airways disease.Study of the metabolites of bencycloquidium bromide racemate, a novel anticholinergic compound, in rat bile by liquid chromatography-tandem mass spectrometry.Association of beta2-adrenoreceptor genotypes with bronchodilatory effect of tiotropium in COPD.Prophylactic penehyclidine inhalation for prevention of postoperative pulmonary complications in high-risk patients: study protocol of a randomized controlled trial.Evaluation of an agonist index: affinity ratio for compounds active on muscarinic cholinergic M2 receptors.Determination of bencycloquidium bromide, a novel anticholinergic compound, in rat tissues by liquid chromatography-electrospray ionization mass spectrometry.Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues.
P2860
Q26825822-10051D19-2138-400F-A5AF-0099DE88153EQ29248924-B38F680C-784A-4860-AF79-B05FA692AA2AQ34074654-8CAEB3AE-8E0F-4D6E-9BAB-931F9D48C62EQ34204383-BBBD3E22-2A71-4949-ACCB-69C25088151CQ34443155-A2936D45-41E6-4801-B582-6363A70207C8Q34534425-A1A4CD19-3299-480F-995B-586BD942EA6FQ35533134-31A7BC6C-D5EB-4070-984C-1FD05EECC6AFQ35533708-A464352D-0320-40D0-8739-4AECCA371C72Q35873499-2105CD52-5417-4DED-823C-249DFF704BD6Q36200675-267BDA06-A635-4424-94E0-19AFE53C724CQ36668046-DB1889BD-CD05-4F0A-B6CE-F92B68CE5FDDQ36859393-ADD24D01-9EC3-4D5F-A3CE-F9E97DF86521Q37017248-008E25E0-1018-4B27-A67B-7531DB6DAF23Q37153289-3869024B-2EF8-4D55-B81F-8A7D911645EAQ38074513-31619D17-4ECE-4B3F-9794-0FC3B7CE7992Q38131050-D9822F12-3B1A-452C-ACC3-4CC888DB53CFQ38256783-EB52CBD5-A5BD-4F59-A8CA-D1866627BD18Q38592062-96211724-BC7C-4DBD-BE05-CF3C7F3AA288Q38779411-A24DE142-2870-435E-98DF-D8C5973974E9Q38974241-23341078-EE6C-4A34-BF84-D2207F042C4DQ39090248-11BA8A38-875A-4B89-B5BB-A199F95A058CQ39299438-6620D08C-18F2-4A5A-8F6C-A0C755989860Q39386571-41763217-53BC-485E-AA77-75615BA8D038Q40996070-FB718DAB-3E94-4806-B2B0-81644C74B810Q41722430-D51B9882-3EB8-4C64-B7F5-3462E39F2509Q43124360-8DDECB1B-163E-44F5-962A-E455DEFDA166Q44336372-49ACFA06-6B86-46FE-952D-85D9AF54F680Q44429216-B126772E-B82C-41E2-8E30-3D7B9F202666Q44719201-C41A6733-F2B9-4E1E-870F-0E068097FE4DQ46102412-878FE083-47EC-4898-8A5E-E112E10C714BQ46584991-186EA29F-3032-4DDD-B980-32D037829693Q46654964-03A1BC5E-DA58-44DE-B1DD-F56CB9B52A0EQ47149294-9B66ADB3-A67D-4B10-8904-47AE04AC7993Q48124434-AFA9650C-93A0-4A95-8DC0-82E6CA44F310Q48819152-70FA7443-D7EC-4228-AF95-8F679C8DD7F1Q55284121-C1341FF6-EABA-442F-B497-3B9BA988175C
P2860
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Muscarinic receptor subtypes in airways.
@en
type
label
Muscarinic receptor subtypes in airways.
@en
prefLabel
Muscarinic receptor subtypes in airways.
@en
P1433
P1476
Muscarinic receptor subtypes in airways.
@en
P2093
P304
P356
10.1016/0024-3205(93)90310-Y
P407
P577
1993-01-01T00:00:00Z